1 – 24 of 24
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
- 2016
-
Mark
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
(
- Contribution to journal › Article
- 2014
-
Mark
Definitions in hemophilia: communication from the SSC of the ISTH
(
- Contribution to journal › Article
- 2012
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group.
(
- Contribution to journal › Article
- 2009
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
(
- Contribution to journal › Debate/Note/Editorial
- 2008
-
Mark
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors
(
- Contribution to journal › Article
-
Mark
Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)
(
- Contribution to journal › Article
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
- 2006
-
Mark
Are randomized clinical trials the only truth? Not always
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
- 2005
-
Mark
Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada.
(
- Contribution to journal › Article
- 2004
-
Mark
Optimizing factor prophylaxis for the haemophilia population: where do we stand?
(
- Contribution to journal › Article
- 2003
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
- 2002
-
Mark
Anti-D (WinRho SD™) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
- 2001
-
Mark
Optimal treatments for patients with bleeding disorders.
(
- Contribution to journal › Letter
- 1997
-
Mark
Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura
(
- Contribution to journal › Article
-
Mark
Induction of a secondary human anti-HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes
(
- Contribution to journal › Article
- 1996
-
Mark
Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura : relationship to platelet phenotype and antiplatelet T-cell reactivity
(
- Contribution to journal › Article
- 1995
-
Mark
Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation
(
- Contribution to journal › Article
- 1993
-
Mark
Downregulation of the anti-HLA alloimmune response by variable region- reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates
(
- Contribution to journal › Article